There's another possible explanation for the drop in the share price this week. It appears to coincide with the end of the deferral period for 11.3 million shares issued as part of the Potential(x) acquisition at the end of August 2021. See this extract from their Investor Presentation released to the ASX...
Unfortunately none of the Potential(x) management team are still at Beamtree AFAIK... at least none are listed on the Beamtree website any more...
This suggests that any shares issued to these folks might be up for sale now, if they don't think the share price will recover in the near future.
It might also explain the big increase in share volume in the last few days since the release of the annual results. At 21 cents a share, they can get about one-third of the original value of the shares when they were issued.
Unfortunately, even at 21 cents per share, the company is still valued at about 2.5 times total revenue, and booked a net loss (after tax) of 6.5 million in 2023.
- Forums
- ASX - By Stock
- BMT
- Ann: FY23 Results Announcement
Ann: FY23 Results Announcement, page-19
-
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BMT (ASX) to my watchlist
(20min delay)
|
|||||
Last
24.5¢ |
Change
0.005(2.08%) |
Mkt cap ! $70.98M |
Open | High | Low | Value | Volume |
24.5¢ | 24.5¢ | 24.5¢ | $2.205K | 9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 24.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
25.0¢ | 3479 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 0.245 |
2 | 62358 | 0.240 |
1 | 24999 | 0.235 |
1 | 50000 | 0.230 |
2 | 20444 | 0.225 |
Price($) | Vol. | No. |
---|---|---|
0.250 | 3479 | 1 |
0.255 | 21124 | 1 |
0.260 | 49604 | 3 |
0.275 | 7682 | 1 |
0.280 | 32000 | 1 |
Last trade - 10.17am 13/11/2024 (20 minute delay) ? |
Featured News
BMT (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online